Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Ampol Profit Surges as Refining Margins Hit Record Highs 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Trump Buys SpaceX Shares After Record IPO 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
SK Hynix Shares Fall as Workers Reject Wage Deal 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Add as a preferred source on Google
IRVINE, Calif., May 03, 2018 -- Evolus, Inc. (NASDAQ:EOLS) (“Evolus”), a lifestyle aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today announced that Murthy Simhambhatla, President and Chief Executive Officer is scheduled to present at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas, NV.
Event: Bank of America Merrill Lynch 2018 Health Care Conference
Date: Thursday, May 17, 2018
Time: 10:00 a.m. PT
Location: The Encore, Las Vegas, NV
An audio webcast of the Company’s presentation will be available on the investor relations section of Evolus’ website at www.Evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation.
The Company will also be hosting one-on-one investor meetings at the conference on Wednesday, May 16. If interested in meeting with management, please reach out to Brian Johnston at [email protected] or your Bank of America Merrill Lynch contact.
About Evolus, Inc.
Evolus is a medical aesthetics company dedicated to bringing advanced aesthetic procedures and treatments to physicians and consumers. Evolus focuses on the self-pay aesthetic market and its lead product candidate DWP-450 (prabotulinumtoxinA), an injectable 900 kDa purified botulinum toxin type A complex.
Evolus Contacts:
Media:
Kirsten Thomas, The Ruth Group
Tel: +1-508-280-6592
Email: [email protected]
Investor Contact:
Brian Johnston, The Ruth Group
Tel: +1 646-536-7028
Email: [email protected]
